The content on this site is intended for healthcare professionals only
ESMO 2022: Best approaches to bladder preservation
Prof Morgan Rouprêt and Prof Nick James
27 Sep 2022
Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
25 Sep 2022
Cancer survivors' stories: An African perspective
Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation
15 Sep 2022
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible loca...
Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York Cit...
14 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
12 Sep 2022
Updates in prostate cancer from ESMO 2022
Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik
12 Sep 2022
Latest in mRCC from ESMO 2022
Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Ou...
12 Sep 2022
ESMO 2022: Renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
12 Sep 2022
Emerging systemic therapies in rare urothelial cancer variants
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
12 Sep 2022
Lenvatinib plus pembro for aRCC - update on the CLEAR study
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
12 Sep 2022
RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy...
Prof Chris Parker - Institute of Cancer Research, Sutton, UK
12 Sep 2022
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer
Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürma...
11 Sep 2022